Cargando…
Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting
Transrectal ultrasound (TRUS) biopsy can miss 20–30% of clinically significant cancers. We evaluate an alternative approach—transperineal template-guided mapping biopsy (TTMB) in the initial and repeat biopsy setting. From January 2005 through September 2008, 373 consecutive men underwent TTMB (294...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834351/ https://www.ncbi.nlm.nih.gov/pubmed/19786982 http://dx.doi.org/10.1038/pcan.2009.42 |
_version_ | 1782178563303145472 |
---|---|
author | Taira, A V Merrick, G S Galbreath, R W Andreini, H Taubenslag, W Curtis, R Butler, W M Adamovich, E Wallner, K E |
author_facet | Taira, A V Merrick, G S Galbreath, R W Andreini, H Taubenslag, W Curtis, R Butler, W M Adamovich, E Wallner, K E |
author_sort | Taira, A V |
collection | PubMed |
description | Transrectal ultrasound (TRUS) biopsy can miss 20–30% of clinically significant cancers. We evaluate an alternative approach—transperineal template-guided mapping biopsy (TTMB) in the initial and repeat biopsy setting. From January 2005 through September 2008, 373 consecutive men underwent TTMB (294 men with ⩾1 prior negative biopsy and 79 men as the initial biopsy). The location of each positive biopsy core, number of positive cores, and percent involvement of each core was recorded. Cancer detection rate for the initial biopsy was 75.9%. For men with 1, 2, and ⩾3 prior negative biopsies detection rates were 55.5%, 41.7%, and 34.4%, respectively. In all, 55.5% of the cancers identified were Gleason ⩾7. The majority of the cancers were multifocal. There was no significant change in the number of positive cores or Gleason score as the number of prior biopsies increased. The anterior and apical aspects of the prostate were among the most common cancer locations. TTMB provides a high rate of cancer detection as initial and repeat biopsy. TTMB was particularly effective at diagnosing anterior and apical cancer. TTMB may have particular application for men considering active surveillance, with prior negative TRUS biopsies, and those considering subtotal gland or other minimally invasive treatments. |
format | Text |
id | pubmed-2834351 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-28343512010-03-29 Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting Taira, A V Merrick, G S Galbreath, R W Andreini, H Taubenslag, W Curtis, R Butler, W M Adamovich, E Wallner, K E Prostate Cancer Prostatic Dis Original Articles Transrectal ultrasound (TRUS) biopsy can miss 20–30% of clinically significant cancers. We evaluate an alternative approach—transperineal template-guided mapping biopsy (TTMB) in the initial and repeat biopsy setting. From January 2005 through September 2008, 373 consecutive men underwent TTMB (294 men with ⩾1 prior negative biopsy and 79 men as the initial biopsy). The location of each positive biopsy core, number of positive cores, and percent involvement of each core was recorded. Cancer detection rate for the initial biopsy was 75.9%. For men with 1, 2, and ⩾3 prior negative biopsies detection rates were 55.5%, 41.7%, and 34.4%, respectively. In all, 55.5% of the cancers identified were Gleason ⩾7. The majority of the cancers were multifocal. There was no significant change in the number of positive cores or Gleason score as the number of prior biopsies increased. The anterior and apical aspects of the prostate were among the most common cancer locations. TTMB provides a high rate of cancer detection as initial and repeat biopsy. TTMB was particularly effective at diagnosing anterior and apical cancer. TTMB may have particular application for men considering active surveillance, with prior negative TRUS biopsies, and those considering subtotal gland or other minimally invasive treatments. Nature Publishing Group 2009-09-29 2010-03 /pmc/articles/PMC2834351/ /pubmed/19786982 http://dx.doi.org/10.1038/pcan.2009.42 Text en Copyright 2010, Nature Publishing Group http://creativecommons.org/licenses/by-nc-nd/3.0/ This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/3.0/ |
spellingShingle | Original Articles Taira, A V Merrick, G S Galbreath, R W Andreini, H Taubenslag, W Curtis, R Butler, W M Adamovich, E Wallner, K E Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting |
title | Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting |
title_full | Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting |
title_fullStr | Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting |
title_full_unstemmed | Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting |
title_short | Performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting |
title_sort | performance of transperineal template-guided mapping biopsy in detecting prostate cancer in the initial and repeat biopsy setting |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834351/ https://www.ncbi.nlm.nih.gov/pubmed/19786982 http://dx.doi.org/10.1038/pcan.2009.42 |
work_keys_str_mv | AT tairaav performanceoftransperinealtemplateguidedmappingbiopsyindetectingprostatecancerintheinitialandrepeatbiopsysetting AT merrickgs performanceoftransperinealtemplateguidedmappingbiopsyindetectingprostatecancerintheinitialandrepeatbiopsysetting AT galbreathrw performanceoftransperinealtemplateguidedmappingbiopsyindetectingprostatecancerintheinitialandrepeatbiopsysetting AT andreinih performanceoftransperinealtemplateguidedmappingbiopsyindetectingprostatecancerintheinitialandrepeatbiopsysetting AT taubenslagw performanceoftransperinealtemplateguidedmappingbiopsyindetectingprostatecancerintheinitialandrepeatbiopsysetting AT curtisr performanceoftransperinealtemplateguidedmappingbiopsyindetectingprostatecancerintheinitialandrepeatbiopsysetting AT butlerwm performanceoftransperinealtemplateguidedmappingbiopsyindetectingprostatecancerintheinitialandrepeatbiopsysetting AT adamoviche performanceoftransperinealtemplateguidedmappingbiopsyindetectingprostatecancerintheinitialandrepeatbiopsysetting AT wallnerke performanceoftransperinealtemplateguidedmappingbiopsyindetectingprostatecancerintheinitialandrepeatbiopsysetting |